Form 8-K for Press Releases




SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported) May 30, 2006

CHEMBIO DIAGNOSTIC, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
0-30379
 
88-0425691
(State or other jurisdiction
 
(Commission File Number)
 
(IRS Employer
of Incorporation)
     
Identification Number)
   
3661 Horseblock Road
   
   
Medford, NY 11763
   
   
(Address of principal executive offices)
   
   
631-924-1135
   
   
(Registrant’s Telephone Number)
   
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
ITEM 7.01. Regulation FD Disclosures.

 
(a)
On May 30, 2006 the Registrant issued the press release titled “Chembio Receives FDA Approval for its Rapid HIV Tests” included herein as Exhibit 99.1.

 
(b)
On May 31, 2006 the Registrant issued the press release titled “Chembio to Participate in the United Nations High Level Meetings on Aids” included herein as Exhibit 99.2.

ITEM 9.01. Financial Statements and Exhibits
 
(c) Exhibits.

99.1
Press Release titled “Chembio Receives FDA Approval for its Rapid HIV Tests” issued May 30, 2006.
99.2
Press Release titled “Chembio to Participate in the United Nations High Level Meetings on Aids” issued May 31, 2006.
 
 


 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: May 31, 2006    Chembio Diagnostics, Inc.

By:    /s/ Lawrence A. Siebert  
Lawrence A. Siebert
Chief Executive Office